Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Takeda to Procure €7.5 Billion in Bonds for Shire Acquisition
November 19, 2018
- AstraZeneca Japan Set to Roll Out 4 New Treatments Every Year through 2021: Chief
November 16, 2018
- Talion AG Contributes to Nipro’s Strong Generic Biz Growth
November 16, 2018
- Novo to Develop New Dosages for Ozempic, 14-Day Prescription Limit Weighs
November 16, 2018
- NapaJen Pharma Initiates PI Trial of Oligonucleotide Therapeutic in Australia
November 16, 2018
- Hib Vaccine Wind-Up, Development Flop Trigger GSK, Daiichi Sankyo to Shutter JV
November 15, 2018
- Meiji Seika Pharma to Venture into Eye-Care Field in Indonesia in Collaboration with Santen
November 15, 2018
- Nichi-Iko Places Top Priority on Product Launches in the US in Biosimilar Business: President
November 14, 2018
- GSK, Daiichi Sankyo Dissolve Vaccine JV
November 14, 2018
- Sumitomo Dainippon Establishes JV with Sumitomo Bakelite through Transfer of Diagnostics Biz
November 13, 2018
- Santen Aims at 1st-Line Use of Eybelis for Glaucoma Treatment: President
November 13, 2018
- Big Takeda Could Debut as Early as January 8, De-facto Vote on Shire Deal Set for Dec. 5
November 13, 2018
- Takeda: De-facto Vote on Shire Deal Set for Dec. 5
November 12, 2018
- Japan Is Top Strategic Market for Biogen: CEO
November 12, 2018
- Ethical Drug Sales Down 8.1% in September: Crecon
November 12, 2018
- Avastin Tops Japan Sales Ranking for 3 Months on End: Encise Snapshot
November 12, 2018
- Nippon Kayaku’s Herceptin Biosimilar to Foray into Breast Cancer Arena, following Daiichi Sankyo, Pfizer
November 12, 2018
- Eisai Launches Full-Scale Operations at New China Plant, Doubling Production Capacity
November 12, 2018
- EA Pharma Pairs Up with 6 Institutions on Joint Research on Novel Antibody for Crohn’s Disease
November 9, 2018
- Maviret Retains Top Spot in Japan Drug Ranking in July-September: IQVIA
November 8, 2018
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…